Table 1.
Baseline characteristics of patients in the immune-tolerant, HBeAg-positive immune -activity, inactive, HBeAg-negative immune-activation, and GZ groups.
| Factor | Immune-tolerant CHB | HBeAg-positive immune-active CHB | Inactive CHB | HBeAg-negative immune-active CHB | GZ | P-value |
|---|---|---|---|---|---|---|
| N | 282 | 912 | 3,502 | 717 | 2,906 | |
| Sex (male) | 157 (55.7%) | 606 (66.4%) | 2,158 (61.6%) | 517 (72.1%) | 1,978 (68.1%) | <0.001 |
| AGE, median (IQR) | 34 (26, 46) | 36 (28, 47) | 54 (45, 64) | 49 (40, 58) | 50 (39, 59) | <0.001 |
| HT | <0.001 | |||||
| 0 | 260 (92.2%) | 847 (92.9%) | 2,401 (68.6%) | 591 (82.4%) | 2,255 (77.6%) | |
| 1 | 22 (7.8%) | 65 (7.1%) | 1,101 (31.4%) | 126 (17.6%) | 651 (22.4%) | |
| DM | <0.001 | |||||
| 0 | 273 (96.8%) | 856 (93.9%) | 2,893 (82.6%) | 615 (85.8%) | 2,498 (86.0%) | |
| 1 | 9 (3.2%) | 56 (6.1%) | 609 (17.4%) | 102 (14.2%) | 408 (14.0%) | |
| ALT, median (IQR) | 20 (16, 24) | 78 (47, 173.5) | 17 (13, 22) | 68 (46, 134) | 42 (23, 82) | <0.001 |
| AST, median (IQR) | 22 (19, 25) | 58 (37, 113.5) | 22 (18, 26) | 57 (37, 110) | 34 (24, 66) | <0.001 |
| TBIL, median (IQR) | 10 (7, 13) | 13 (9, 20) | 10 (7, 14) | 14 (10, 22) | 12 (9, 20) | <0.001 |
| ALB, median (IQR) | 41.25 (36.2, 45.3) | 40.5 (35.5, 45.8) | 40.3 (36, 44.1) | 38 (32.8,43) | 39.9 (34.8,44.1) | <0.001 |
| Plt, median (IQR) | 209.5 (179, 252) | 178 (135, 220) | 201 (159, 245) | 174 (124,216) | 187 (141, 231) | <0.001 |
| PT, median (IQR) |
13.5 (12.9, 14.1) | 13.7 (12.9,14.5) | 13.9 (13.2, 15.1) | 13.7 (13, 14.3) | 13.6 (13,14.4) | <0.001 |
| HBVDNA, median (IQR) | 1.4E+8 (6.20E+7, 2.80E+8) | 1.3E+7 (9.95E+, 1.05E+8) | 290 (30,500) | 7.5E+4 (8,900, 8.30E+5) | 500 (44, 3,700) | <0.001 |